【摘 要】
：
Objective To clear the optimal time of concurrent thoracic radiotherapy (TRT) with etoposide and cisplatin/carboplatin (EP/EC) chemotherapy for limited-disease small cell lung cancer (LD SCLC).Methods
【机 构】
：
Zhejiang Key Laboratory of Diagnosis and Treatment Technology on Thoracic Oncology (Lung and Esophag
【出 处】
：
2013年肿瘤多学科综合诊治新进展学术研讨会
论文部分内容阅读
Objective To clear the optimal time of concurrent thoracic radiotherapy (TRT) with etoposide and cisplatin/carboplatin (EP/EC) chemotherapy for limited-disease small cell lung cancer (LD SCLC).Methods Randomized controlled trials were identified according to MEDLINE, the Cochrane Central Register of Controlled Trials, EMBASE, and so on comparing early to late concurrent TRT with EP/EC chemotherapy for LD SCLC.Early thoracic radiotherapy (ERT) was defined as beginning radiation within 30 days after the start of chemotherapy.Results There are three eligible randomized controlled trials.No significance difference in objective response was detected between early concurrent TRT and late concurrent TRT (RR: 1.01, 95% CI 0.86-1.18, P=0.90).Similar result was detected in 1-, 2-, 3-, and 5-year survival rates between early concurrent TRT and late concurrent TRT (RR: 1.06, 95% CI 0.88-1.27, P=0.56; RR: 1.15, 95% CI 0.77-1.71, P=0.49; RR: 0.90, 95% CI 0.66-1.22, P=0.49; RR: 1.18, 95% CI 0.64-2.16, P=0.60).Total grade 3-4 adverse events including anemia, leucopenia, neutropenia, thrombocytopenia, nausea and vomiting, infection, esophageal toxicity, pulmonary toxicity, alopecia and hemorrhage in early concurrent TRT were significantly higher than that in late concurrent TRT (RR: 1.21, 95% CI 1.03-1.43, P=0.02).Conclusion The result of our work indicates that survival rate of LD-SCLC with late concurrent TRT combined EP/EC chemotherapy is similar with early concurrent TRT, while grade 3-4 adverse events were less.
其他文献
Evidence shows that Bcl-2 family members play a direct role in the development of some human malignancies.However, the mechanism by which Bcl-2 may influence tumor cell invasion and metastasis remains
目的 肿瘤组织通常存在于缺氧环境中,糖酵解作用增强.为了避免凋亡,及时泵出细胞内H+,肿瘤细胞常高表达质子泵转运蛋白(v-ATPase)及Na+-H+交换泵(NHE).因此,我们联合使用埃索美拉唑与阿米洛利,观察对荷瘤裸鼠肿瘤生长转移的影响,并探讨其内在机制.方法 将人肺癌A549细胞接种于裸鼠背部皮下建立移植瘤模型,当肿瘤长150mm3时,随机分为2组：对照组与联合用药组(埃索美拉唑40mg/k
目的 揭示细胞衰老与慢性肝损伤至肝细胞肝癌的发病机制。方法 通过临床观测及Pubmed相关文献复习。结果 发现颇为丰富的研究资料显示，众多与肝癌发生相关的危险因素的基本致癌机制是慢性持续性肝损伤。即慢性肝损伤是肝细胞癌的基本成因。频繁的抗损伤修复导致肝细胞早衰性衰老使肝干细胞突变几率增大。结论 慢性肝脏损害可致肝细胞衰老并刺激肝卵原细胞(肝祖细胞)活跃增殖，后者属于分化前途未定的多分化潜能细胞，具
Objective To assess the efficacy and safety of neoadjuvant chemotherapy (NAC) for advanced gastric cancer (AGC).Methods By searching electronic databases (PubMed, Embase, Cochrane Library) and ASCO pr
Objective Whether laparoscopic-assisted surgery can achieve the same oncologic outcomes compared with open surgery for rectal cancer remains controversial.The aim of this meta-analysis of randomized c
目的 比较晚期老年非小细胞肺癌应用吉非替尼和培美曲塞治疗的疗效及毒副反应.方法 经过细胞学或病理学确诊的老年(年龄≥70岁)晚期非小细胞肺癌患者56例,随机分为吉非替尼组30例,服用吉非替尼250 mg,每日2次,直至肿瘤进展或出现无法耐受的毒副作用.培美曲塞组26例,培美曲塞500 mg/m2静脉滴注治疗,每3周重复,至少化疗2周期.观察疗效及毒副反应.结果 口服吉非替尼治疗的患者CR3.3％(
目的 研究肿瘤特异生长因子检测在消化道肿瘤诊断及放射介入治疗效果观察中应用的意义.方法 用日立7100型全自动生化分析仪对60例消化道恶性肿瘤患者,40例正常人,25例良性瘤患者及45例恶性肿瘤患者采取放射介入治疗治疗后血清肿瘤特异生长因子(TSGF)进行检测分析.结果 消化道恶性肿瘤患者血清TSGF浓度明显高于正常对照组和良性肿瘤患者,并且消化道恶性肿瘤患者治疗后血清TSGF浓度明显比治疗前低.
目的 应用尿液中胸腺素alpha原作为肿瘤标记物进行膀胱癌诊断。方法 应用本实验室制备的胸腺素alpha原单克隆抗体,采用斑点杂交方法,以病人尿液为检测对象,以正常人尿液为对照,检测不同尿样中胸腺素alpha原表达水平。结果 由三甲医院提供的确诊为膀胱癌的病人的尿液为实验组,共28例,同时以健康人尿液为对照组,共50例,进行检测。结果发现,病人尿液中胸腺素alpha原检测,25例为强阳性,3例为弱
目的 用现代舌象仪对湿热型肝癌患者肝动脉栓塞化疗(TACE)前后舌象进行动态观察,尝试建立湿热型肝癌舌象的客观化依据,并探讨TACE治疗前后患者舌象的变化,为术后中医治疗提供一种规律性指导.方法 收集符合肝癌西医诊断标准及中医湿热型肝癌诊断标准的患者142例,所有患者均接受肝动脉栓塞化疗术(TACE)；分别于介入术前、术后3天及术后1周利用舌象仪采集舌象,采集前半小时嘱患者清水漱口后禁食,采集前5
目的 研究肿瘤特异生长因子检测在妇科肿瘤诊断及放射介入治疗效果观察中应用的意义.方法 用日立7020型全自动生化分析仪对62例消化道恶性肿瘤患者,45例正常人,20例良性瘤患者及40例妇科恶性肿瘤患者治疗后血清肿瘤特异生长因子(TSGF)进行检测分析.结果 妇科恶性肿瘤患者血清TSGF浓度明显高于正常对照组和良性肿瘤患者,并且妇科恶性肿瘤患者治疗后血清TSGF浓度明显比治疗前低.血清TSGF测定对